Quantification of tumor suppressor mRNA expression by poly-competitive RT-PCR using a TS-IS that contained multiple internal competitors. by 諛뺤쟾�븳
Demo
Mol. Cells, Vol. 13, No. 3, pp. 481-487 
 
 
 
 
 
 
Quantification of Tumor Suppressor mRNA Expression by  
Poly-competitive RT-PCR Using a TS-IS that Contained  
Multiple Internal Competitors 
 
Hee-Jung Jung, Ji Hyung Chae, Hoguen Kim1, Jeon Han Park2, Jong Soo Lee, Woong Hwan Choi3, and 
Chul Geun Kim* 
Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 133-791, Korea; 
1 Department of Pathology, Yonsei University College of Medicine, Seoul 120-749, Korea;  
2 Department of Microbiology, Yonsei University College of Medicine, Seoul 120-749, Korea;  
3 Department of Internal Medicine, College of Medicine, Hanyang University, Seoul 133-792, Korea.  
 
(Received February 2, 2002; Accepted March 22, 2002) 
 
Despite the recent introduction of real-time PCR 
methods and cDNA microarrays, competitive PCR 
techniques continue to play an important role in nu-
cleic acid quantification because of the significantly 
lower cost of equipment and consumables. In this 
study, we developed a construct, termed tumor sup-
pressor-internal standard (TS-IS) that produced poly-
competitive RNA templates as an internal standard to 
quantify cellular RNA concentration of tumor sup-
pressor genes. This construct is composed of not only 
sets of primers for detecting the expression of several 
tumor suppressor genes (such as pRB, p16INK4A, 
p15INK4B, p14ARF, p53, and p21WAF1), but also HPRT as 
an endogenous marker. Using an internal standard 
RNA that was synthesized from the TS-IS construct, 
we were able to establish optimized conditions for the 
quantification of tumor suppressor genes with mini-
mal amounts (50 ng) of cellular RNA. In addition, the 
usefulness of this method was confirmed by analyzing 
the expression levels of tumor suppressor genes in 
fourteen hepatoma cell lines as a model. The TS-IS 
assay that we used was inexpensive and a widely ap-
plicable method that permitted the reliable and accu-
rate quantification of tumor suppressor genes.  
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Introduction 
 
Cancer is a disease that has an abnormal and unregulated 
proliferation of cells. The changes in its genome results in 
the formation of a malignant tumor (Hanahan and 
Weinberg, 2000). Although there is a lot of information 
on cancer biology, present cancer therapies are seriously 
limited in overcoming the complexity of cancer. In order 
to have a good cancer treatment, it is necessary to make 
an early diagnosis and analysis of the cancer-related ge-
netic status of patients. An analysis of the developmental 
mechanism that governs the transformation of normal 
human cells to malignant cancers at the molecular and 
genetic levels will mark a departure point in several direc-
tions for the treatment and prevention of cancer. 
   According to advanced genetic research, multiple ge-
netic alterations that occur in human cancer target both 
oncogenes and tumor suppressor genes (Biden et al., 
1997; Hollstein et al., 1991; Levine et al., 1991; Sherr, 
1998). Recessive functional loss of tumor suppressor 
genes, such as p14ARF, p15INK4B, p16INK4A, p21WAF1, p53, 
and pRb, is central to the tumorigenesis process (Levine 
et al., 1991; Weinberg, 1995). The expression level and 
pattern of tumor suppressor genes depend on tumor types 
and their progressiveness (Kamijo et al., 1997; Markl and 
Jones, 1998). Therefore, a rapid and accurate analysis of 
the expression profile of tumor suppressor genes and their 
genetic status will provide valuable tools for the diagnosis 
and determine the direction of medical treatment.  
 
Abbreviations: DTT, dithiothreitol; FBS, fetal bovine serum; 
HPRT, hypoxanthine phosphoribosyl transferase; Rb, Retino-
blastoma; RT-PCR, reverse transcription-polymerase chain reac-
tion; TS-IS, tumor suppressor-internal standard. 
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   PCR is one of the many tools that have commonly been 
used for the accurate quantification of DNA or RNA. 
Competitive PCR techniques in particular continue to 
play an important role in nucleic acid quantification be-
cause of its significantly lower cost in equipment and 
consumables. The procedure relies on the co-amplifi-
cation of the sequences of interest with a serially diluted 
synthetic DNA fragment of known concentration (com-
petitor) using a single set of primers (Gaiger et al., 1995; 
Lion et al., 1992). The initial quantity of target molecules 
in the sample can be calculated from the ratio of the com-
petitor- and target-derived amplicons that are generated 
during PCR, provided that the target and competitor se-
quences are amplified with equivalent efficiency (Liu and 
Burt, 1998; Vu et al., 2000; Wang et al., 1989).  
   In order to detect the expression level and patterns of 
tumor suppressor genes with reproducibility, accuracy, 
rapidity, and high sensitivity, we constructed a TS-IS vec-
tor that contained primer sequences against not only 6 
essential tumor suppressor genes, but also HPRT as an 
endogenous marker. The devised TS-IS construct pro-
vides a multi-specific cDNA template to detect and quan-
tify the expression of these genes. A competitive RT-PCR 
assay using the TS-IS construct was efficiently carried out 
with fourteen human hepatocellular carcinoma cell lines 
as a model.  
 
 
Materials and Methods 
 
Designing tumor suppressor gene-specific primers  For de-
signing primers specific for each tumor suppressor gene, the 
following considerations were made: (i) Primers should be 
19−20 bases in length. (ii) The primers should have a G/C con-
tent between 55 and 70% and terminate in one or more G or C 
bases. (iii) There should not be any obvious secondary struc-
tures and internal complementary sequences. (iv) The primers 
should be selected from separate exons to distinguish between 
the products that were derived from cDNA and the conta-
minated genomic DNA. In addition, we generated primers for 
the HPRT gene as an internal marker. Forward and reverse 
primers were named 1R and 2R, respectively, except for p15 4R 
that is a universal reverse primer for all of p14, p15, and p16. 
 
Construction of the TS-IS plasmid  A schematic diagram that 
demonstrates the construction of the TS-IS vector is shown in 
Fig. 1. The linker oligomers that were used for joining each of 
the two neighboring primers are as follows: (i) Linker oligomers 
have 6 bp complementary sequences with two adjacent primers 
for tumor suppressor genes to be linked. (ii) Linker oligomers, 
located in the middle of the TS-IS sequences (i.e., between for-
ward primer of p21 and reverse primer of p53), have comple-
mentary sequences to each other with the (GA)4 or (TC)4 as well 
as 6 bp complementary sequences of p21 and p53 (Fig. 1). All 
of the forward or reverse primers and two middle linkers were 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. A flow chart showing the generation and use of the tu-
mor suppressor-internal standard (TS-IS) construct for the quan-
tification of tumor suppressor mRNAs by poly-competitive RT-
PCR assay. 
 
 
phosphorylated separately by T4 polynucleotide kinase 
(Stratagene, USA) before annealing with the matching pair of 
primers. The annealed primers were ligated, gap-filled, then 
subjected to 28 cycles of PCR amplification. The PCR reactions 
were composed of denaturation at 94°C for 30 s, annealing at 
62°C for 30 s, and extension at 72°C for 1 min. The PCR prod-
uct that contained the TS-IS sequences was inserted into the pT7 
Blue vector (Novagen, USA). DNA sequencing in both direc-
tions verified accurate sequences of the TS-IS construct. The 
DNA fragment that contained the TS-IS sequences in the pT7 
Blue vector was subcloned into pcDNA3-poly (A) (Invitrogen, 
USA), so that the TS-IS sequences were located between the T7 
polymerase promoter and the poly (A) tail. This construct was 
named pcDNA3-TS-IS-poly (A). 
 
The cRNA transcription from the TS-IS  The pcDNA3-TS-
IS-poly (A) plasmid was linearized with XhoI and transcribed in 
vitro using T7 RNA polymerase (Boehringer Mannheim, Ger-
many). The in vitro transcription mixtures were digested with 
RNase-free Dnase I to remove the template DNA. The cRNA 
was purified with RNAzol B (TEL-TEST, USA) and sepa-
rated by size exclusion chromatography. The amount of cRNA 
was estimated by spectrophotometry. Its size and integrity were 
examined by agarose gel electrophoresis (Park et al., 1996). 
 
Cell culture and RNA preparation  The fourteen human hepa-
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tocellular carcinoma cell lines - SK-Hep1, HepG2, HepG2.2.15, 
Hep3B, Chang liver, PLC/PRF5, SNU182, SNU354, SNU368, 
SNU387, SNU398, SNU423, SNU449, and SNU475 - were 
maintained in a RPMI medium 1640 (Gibco-BRL, USA) that 
contained 10% fetal bovine serum (Hyclone, USA) (Kim et al., 
2001). The human primary mesengial cells (a kind gift from Dr. 
Ku Kong, Hanyang University School of Medicine) and the 
peripheral blood mononuclear cell (PBMC) were separated from 
the blood of five normal humans. The normal liver tissue was 
obtained from Hepatocellular carcinoma (HCC) tumor tissues 
by micro-dissection in a cryostat. Total RNA was purified from 
the cells or tissues with RNAzol B (TEL-TEST, USA). The 
purity and quantity of the total RNA were spectrophotometri-
cally estimated. 
 
Reverse transcription and poly-competitive PCR  Five hun-
dred ng of TS-IS cRNA and 1 µg of total cellular RNA from 
hepatoma cell lines were separately reverse-transcribed. The 
total cDNA that was derived from the cellular RNA of each cell 
line was used for a competitive PCR reaction along with the TS-
IS cDNA as an internal control. The amount of TS-IS RNA that 
was used is as follows: 10−3−10−6ng for HPRT and p21; 
10−4−10−7 ng for p14ARF and p16INK4A; 10−5−10−8 ng for p15INK4B, 
p53, and pRb. Thirty-five cycles of the PCR reaction were car-
ried out at 94°C for 30 s, 62°C for 30 s, and 72°C for 1 min in 
the presence of 1 µCi of [α]P32 dCTP. The PCR products were 
separated by electrophoresis in 5% polyacrylamide gel and ex-
posed to the X-ray film after gel drying. Relative fluorescent 
intensity for each PCR product was determined with the BIO-
PROFIL image analysis software, BIO-1D (Vilber Lourmat). 
 
 
Results and Discussion 
 
Construction of the TS-IS plasmid  We made a con-
struct pcDNA3-TS-IS-poly(A) to produce internal com-
petitor standards for the quantitative analysis of the ex-
pression levels of key tumor suppressor genes. The sche-
matic drawing of this construct is shown in Fig. 2A. Spe-
cific primers for the 6 tumor suppressor genes, p14ARF, 
p15INK4b, p16 INK4a, p21, p53, and pRB, were designed 
with considerations that are explained in Materials and 
Methods. In addition, in order to monitor the quality and 
quantity of the total cellular RNA that was prepared from 
the diverse samples, primer sequences for an internal con-
trol marker (HPRT gene) were also incorporated into the 
construct. The relative positions of the primer pairs were 
arranged in order to yield 56−335 bp length differences 
between the PCR products of cellular target RNAs and the 
TS-IS cRNA (Figs. 2A and 2B). The correct size of the 
PCR product was observed when TS-IS cRNA was sub-
jected to RT-PCR using primer pairs of the tumor sup-
pressor genes (Fig. 2C).  
 
Reliability test of competitive RT-PCR using TS-IS  To  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. A pcDNA3-TS-IS-poly(A) vector efficiently synthesizes 
the internal competitive standard RNA to quantify the expres-
sion of tumor suppressor genes. A. A schematic drawing of the 
construct pcDNA3-TS-IS-poly(A). B. Expected PCR product 
sizes from the endogenous cellular and TS-IS RNAs for each 
tumor suppressor gene in the poly-competitive RT-PCR assay. C. 
A RT-PCR data showing the expected size of each PCR product 
that was synthesized from the TS-IS internal standard. The 
cRNAs were synthesized in vitro from the pcDNA3-TS-IS-
poly(A) using T7 RNA polymerase. Then the first-strand cDNA 
was obtained by a reverse transcription reaction. PCR was per-
formed using a set of tumor suppressor or HPRT gene specific 
primer.  
 A 
B 
C 
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Table 1. Estimation of numbers of total mRNA in reactions 
containing fixed amounts of TS-IS by method A 
TS-IS(ng) 10−6 10−5 10−4 10−3 
Numbers of HPRT 
  moleculea 04.8 × 10
3
 04.8 × 104 04.8 × 105 04.8 × 106 
Log Cb 
C (attomole) 
Number of total    
  mRNAc 
0.74 
0.55 × 10 
03.3 × 106 
 
2.20 
1.59 × 102 
09.6 × 107 
 
3.20 
1.59 × 103 
09.6 × 108 
 
4.20 
1.59 × 104 
09.6 × 109 
 
HPRT RNA/ 
  mRNA 1.45 × 10
−3
 00.5 × 10−3 00.5 × 10−3 00.5 × 10−3 
a
 TS-IS of 10−6 ng corresponds to 4.8 × 103 molecules of TS-IS 
RNA that consists of 367 bp.  
b
 To compensate the band intensity between the cellular and TS-IS 
PCR products due to the size difference, we multiplied 2.1 to the 
TS-IS value (i.e., 270 bp/128 bp = 2.1). In the log T/C versus log 
C plot as shown in Fig. 3A, the log C values were obtained where 
log T/C is equal to 0. 
 c
 Numbers of total mRNAs = (C attomole) × (10−18) × (6 × 1023). 
 
 
 
test whether or not competitive RT-PCR using TS-IS is 
reliable, two kinds of experiments were performed on the 
HPRT gene as a control. In the first method (method A), a 
competitive RT-PCR was carried out with fixed amounts 
of the TS-IS RNA (10−6, 10−5, 10−4, or 10−3 ng) and vari-
ous amounts of the cellular total RNA from 800 to 0.78 
ng. Figure 3A shows the represented competitive RT-
PCRs and the plots of the ratio (log T/C) of PCR products 
on a log-log scale as a function of indicated amounts of 
log C. Because the X-axis is the log value of the cellular 
total mRNA (log C) and the Y-axis is the log T/C, the 
value in the X- intercept is the value of log C in which the 
number of cellular total mRNA molecules is equal to that 
of TS-IS RNAs. These values were 0.74, 2.2, 3.2, and 4.2; 
i.e., 3.3 × 106, 9.6 × 107, 9.6 × 108, and 9.6 × 109 mole-
cules of cellular RNA, respectively (Table 1). When the 
values of log C are plotted against log T (Fig. 3B), a lin-
ear regression line was obtained. Therefore, this method 
is reliable whenever any amount of TS-IS is employed in 
the reaction. The average ratio (HPRT RNA/ total mRNA) 
is 0.73 × 10−3 [{(4.8 × 103/3.3 × 106) + (4.8 × 104/9.6 × 
107) + (4.8 × 105/9.6 × 108) + (4.8 × 106/9.6 × 109)} × 1/4]. 
   In the second method (method B), a competitive RT-
PCR was carried out with fixed amounts of the cellular 
total RNA (50 ng) and various amounts of TS-IS RNA 
from 10−3 to 10−6 ng. Figure 4 shows a representative 
competitive RT-PCR and a plot of values of log C/T ver-
sus log T. The log T value on the X-intercept is − 3.14; 
therefore, the amount of TS-IS RNA is equal to 10−3.14 ng 
(i.e., 3.5 × 106 molecules of TS-IS RNA) (Table 2). The 
ratio (HPRT RNA/total mRNA) that is estimated from 
method B is 1.2 × 10−3 (= 3.5 × 106/2.9 × 109), and this 
value is quite consistent with the average value of method 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Competitive RT-PCR analysis for the quantification of 
the cellular mRNA level in the reactions containing fixed 
amounts of TS-IS (method A). A. Plots of the ratio (log T/C) of 
the PCR products on a log-log scale as a function of the indi-
cated amounts of log C (upper panels) and the representative 
competitive RT-PCR data (lower panels). Concentration of cel-
lular HPRT mRNA was estimated from the value of log C in the 
X-intercept. Filled arrows indicate the PCR products that were 
produced from the cellular RNA; open arrows represent those of 
the internal standard TS-IS. B. A linear regression plot of the 
values (log T vs. log C) that were obtained from panel A shows 
that the estimation of endogenous cellular HPRT mRNA con-
centration is reliable when any amount of TS-IS RNA is em-
ployed.  
 
A (0.73 × 10−3). As the discrepancy of estimation between 
these two methods is less than two fold (i.e., 1.634), both 
methods will be useful for the quantification of the tumor 
suppressor mRNA. It is noteworthy, however, that method 
A requires more cellular RNA than method B. Therefore, 
method B is a better choice.  
 
Expression profile of tumor suppressor genes in hepa-
toma cell lines As a sample of competitive RT-PCR, we 
selected fourteen human hepatocellular carcinoma cell 
 B 
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Table 2. Estimation of numbers of HPRT RNA in a reaction 
containing 50 ng cellular RNA by method B 
Numbers of mRNA moleculea 2.9 × 109 
Log Tb 
T 
Numbers of HPRT RNAsc 
HPRT RNA/mRNA 
−3.14 
10−3.14 
3.5 × 106 
1.2 × 10−3 
a
 We assumed that mRNA corresponds about 5% of total cellular 
RNA and the average size of mRNA is 1.5 kb. 
b
 To compensate the band intensity between the cellular and TS-IS 
PCR products due to the size difference, we multiplied 2.1 to the 
TS-IS value (i.e., 270 bp/128 bp = 2.1). In the log C/T versus log 
T plot as shown in Fig. 4, the log T value was obtained where log 
C/T is equal to 0. 
c
 TS-IS of 10−3 ng corresponds to 4.8 × 106 molecules of TS-IS 
RNA that consists of 367 bp. 
 
 
Table 3. Expression levels of tumor suppressor genes in normal 
and hepatoma cells. The numbers of RNA molecules were esti-
mated by poly-competitive RT-PCR assay. Each numbers repre-
sent number of corresponding RNA molecules in 50 ng of total 
RNA. ND, not detected in this assay. 
Gene 
Status 
Cell 
line/tissue p14 p16 p21 p53 pRB HPRT 
Normal 
 
 
Normal liver 
PBMC 
M esang ial cell 
ND 
ND 
ND 
ND 
ND 
ND 
4.8×107 
4.8×107 
4.8×105 
4.8×105 
4.8×105 
4.8×103 
4.8×105 
4.8×105 
4.8×103 
4.8×106 
4.8×106 
4.8×106 
Tumor 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chang liver 
HepG2 
HepG2.2.15 
SNU182 
SNU368 
Hep3B 
PLC/PRF5 
SNU449 
SNU423 
SNU354 
SNU475 
SNU398 
SK-Hep1 
SNU387 
4.8×103 
<4.8×102 
4.8×104 
4.8×103 
4.8×102 
4.8×103 
4.8×103 
ND 
4.8×103 
4.8×102 
4.8×103 
ND 
ND 
ND 
4.8×103 
4.8×103 
4.8×104 
4.8×103 
4.8×103 
4.8×103 
4.8×102 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
4.8×106 
4.8×106 
4.8×107 
4.8×105 
4.8×106 
4.8×105 
4.8×105 
4.8×106 
4.8×106 
4.8×104 
4.8×106 
4.8×105 
4.8×106 
4.8×106 
4.8×103 
4.8×103 
4.8×104 
4.8×104 
ND 
ND 
48 
4.8×103 
ND 
ND 
ND 
4.8×103 
48 
ND 
4.8×104 
4.8×103 
4.8×105 
4.8×102 
48 
ND 
48 
4.8×103 
ND 
ND 
ND 
ND 
ND 
ND 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
4.8×106 
 
 
lines in which the expression and genomic status of the 
tumor suppressor genes are well known (Table 4). In this 
test, we also prepared total cellular RNAs from normal 
liver tissue, peripheral blood mononuclear cells (PBMC), 
and human primary mesengial cells (HPMC). Cellular 
RNAs and TS-IS cRNA were individually reverse-tran-
scribed, then competitive PCR was performed with 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Competitive RT-PCR analysis for the quantification of 
the cellular mRNA level in the reactions containing fixed 
amounts of cellular RNA (Method B). A plot of the ratio (log 
C/T) of the PCR products on a log-log scale as a function of the 
indicated amounts of log T (upper panel) and the representative 
competitive RT-PCR data (lower panel).  
 
 
method B. The competitive RT-PCR of the HPRT gene 
was carried out with every sample to monitor whether an 
assay would properly perform and make a standard curve 
of a fixed amount of target cDNA against different 
amounts of TS-IS cDNA. The absolute concentration of 
the tumor suppressor mRNA was estimated from the con-
centration of TS-IS that would have given the same inten-
sity to the tumor suppressor mRNA when analyzed (see 
Materials and Methods).  
   Each cell line exhibited a distinct expression pattern of 
six tumor suppressor genes. These results were simplified 
and summarized in Table 3. In the RNAs that were pre-
pared from normal liver tissue, PBMC and HPMC, the 
expression of p14ARF, p15INK4B, and p16INK4A was not ob-
served, although the expression of p21, p53, and pRB was 
detected. On the contrary, in hepatocellular carcinoma cell 
lines, the expression of p14ARF and p16INK4A was found in 
10 of 14 cases (71.4%) and 7 of 14 cases (50.5%), respec-
tively. Their expression levels were variable within a 
range of 10- to 100-fold difference (Table 3). Among the 
7 hepatocellular carcinoma cell lines in which the p16 
expression was not detected, 3 cases had genomic dele-
tions in the INK4 locus encoding p14ARF, p15 INK4B, and 
p16INK4A. The remaining 4 cases had methylation at their 
promoters (Baek et al., 2000; Table 4). The expression of 
pRb was detected in 7 of 14 cases (50.0%), but the level 
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Table 4. Expression and genomic status of tumor suppressor genes in normal and hepatoma cell lines 
p14 p15 p16 p21 p53 pRb 
Cell line 
DNA RNA DNA RNA DNA RNA DNA RNA DNA RNA DNA RNA 
Normal 
Chang liver 
HepG2 
HepG2.2.15 
Hep3B 
SNU182 
PLC/PRF5 
SNU368 
SNU449 
SNU423 
SNU354 
SNU475 
SNU398 
SK-Hep1 
SNU387 
ND 
ND 
ND 
+a 
+a 
+a 
ND 
ND 
-
a
 
+a 
ND 
+a 
+a 
-
a 
-
a
 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
- 
- 
- 
ND 
ND 
ND 
+a 
+a 
+a 
ND 
ND 
-
a
 
+a 
ND 
+a 
+a 
-
a 
-
a
 
- 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
ND 
ND 
+ 
HMa 
WTa 
+a 
ND 
ND 
-
a
 
Ma 
ND 
Ma 
Ma 
-
a 
-
a
 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
ND 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
WTb 
WTc 
MUTb 
MUTd 
MUTe 
MUTd 
MUTd 
MUTd 
MUTd 
MUTd 
MUTd 
WTc 
MUTd 
ND 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
- 
+ 
- 
- 
+ 
- 
- 
- 
- 
- 
- 
+, expression was detected; -, expression was not detected; WT, wild-type; MUT, mutant; ND, not determined; M, methylation of promoter; 
HM, hemimethylation of promoter. 
a
 Baek et al., 2000; b Okamoto et al., 1994; c Lee et al., 1995; d Kang et al., 1996; e Wang et al., 1994; f Mitry et al., 2000. 
 
 
of its expression, even in the detected cells, was much 
lower compared to normal cells. It is noteworthy that, 
although mutations of p53 were found in 10 of 13 cases 
(Table 4), p53 mRNA was detected in 8 of 14 cases 
(57.1%) in this study. We detected the p21 expression in 
all of the 14-cell lines that were tested, regardless of the 
presence of wild-type p53. 
   The p14ARF was repressed by p53 and its expression was 
not detected in several normal tissues (Stott et al., 1998; 
Zindy et al., 1997). Therefore, the p14ARF expression that 
was detected in most of the hepatoma cells in our study 
may be due to the mutation of p53. It is remarkable, how-
ever, that the p14ARF RNA was over-expressed in the 
HepG2 and HepG2.2.15 cells in which the wild-type p53 
was present. It suggests that there are some mechanisms 
that cause the over-expression of p14ARF and p16INK4A in 
the presence of p53 and/or pRb function.  
   These findings suggest that the expression levels of tu-
mor suppressor genes in hepatocellular carcinoma cells 
are very distinct from that of normal liver cells. Moreover, 
hepatocellular carcinoma cells showed very heterogene-
ous expression patterns on tumor suppressor genes, which 
is consistent with intra-tumor heterogeneity. Tumor induc-
tion is a multi-step process that involves the activation of 
oncogenes and the inactivation of tumor suppressor genes. 
Like other cancer, the loss of p53 and/or pRB functions, 
the deletion of genomic INK4 locus that encodes p14ARF, 
p15INK4b, and p16INK4A genes, were thought to be major 
causes of hepatoceullar carcinomas (Baek et al., 2000; 
Biden et al., 1997; Chin et al., 1998; Hollstein et al., 
1991; Kamb, 1995; Kang et al., 1996; Ko and Prives, 
1996; Newcomb et al., 2000; Okamoto et al., 1994). It is 
intriguing that more than one tumor suppressor gene 
shows abnormal expression profiles due to changes in 
their own genomic status or other transcriptional regula-
tors (Hanahan and Weinberg, 2000; Sherr, 1996; 1998; 
Stott et al., 1998; Weinberg, 1995; Zhang et al., 1998). 
The question of whether or not the abnormal expression 
pattern of tumor suppressor genes in hepatocellular carci-
noma cells can explain the prognosis of hepatoceullar 
carcinoma development or their heterogeneous origins is 
still unanswered. To confirm the significance of these 
possibilities, more investigations are needed, including 
our TS-IS-based poly-competitive RT-PCR method. 
 
 
Conclusion  The poly-competitive PCR method that is 
presented here is efficient for the quantification of even 
the low frequency of mRNAs in a sample (Table 3). The 
synthetic internal standard, TS-IS, which contains multi-
ple primer sets, allows the quantification of a number of 
different mRNAs in parallel. It could, therefore, partially 
reduce experimental errors. Since the TS-IS vector con-
tains the HPRT gene-specific primer set, it provides addi-
tional reliability and accuracy to the experimental results. 
As demonstrated by the quantification of the tumor sup-
pressor mRNAs in the fourteen human hepatocellular car-
cinoma cell lines (Table 3), this technique could be useful 
as a tool for cancer typing and/or diagnosis in clinical 
research and treatment.  
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